August 21, 2026

Advisory boards are one of the most vital strategic tools available to Medical Affairs teams. When assembled effectively, they provide unvarnished clinical insights, identify unaddressed patient needs, and shape early-to-late-stage drug development strategies. However, the traditional process of identifying advisors and preparing agendas is increasingly out of step with today’s fast-moving medical landscape. Medical Affairs teams are under immense pressure to move away from legacy networks and build dynamic, data-driven advisory boards that reflect true clinical consensus.

Most commercial teams in life sciences companies already have access to KOL data. What they lack is a reliable way to turn that data into an engagement strategy that works consistently across therapy areas, geographies, and the full range of experts who actually influence treatment decisions. The problem is that commercial KOL engagement doesn’t scale the way most strategies are built. It works well for the most visible national experts, then breaks down as teams move deeper into the landscape. Community opinion leaders, emerging KOLs, and local clinical influencers tend to fall outside the reach of traditional approaches not because intelligence doesn’t exist, but because most platforms aren’t built to connect it in a way commercial teams can act on.